Results 11 to 20 of about 26,226 (199)
Can this be considered a Fondaparinux-induced Thrombocytopenia? [PDF]
European Journal of Case Reports in Internal Medicine, 2014 We present a case of an old woman with previously documented heparin-induced thrombocytopenia (HIT), treated with fondaparinux, who presented with thrombocytopenia and venous thrombosis after exposure to a preventive dose of fondaparinux during ...
Barbara Mariotti +2 more
doaj +2 more sources
Advances in Chemical Synthesis of Fondaparinux
Journal of Chemistry, 2019 Fondaparinux (trade name Arixtra) is a safe and efficacious anticoagulant, and it is chemically related to low-molecular-weight heparins such as enoxaparin. Fondaparinux is a synthetic pentasaccharide, and its synthesis is difficult and expensive.
Yili Ding +2 more
doaj +2 more sources
Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies
Vascular Health and Risk Management, 2010 François SchieleDepartment of Cardiology, University Hospital Jean-Minjoz, Besançon, FranceAbstract: Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS).
François Schiele
doaj +1 more source
Fondaparinux in the management of patients with ST-elevation acute myocardial infarction
Vascular Health and Risk Management, 2006 Alexander GG TurpieHamilton Health Sciences Corporation – General Division, Hamilton, ON, CanadaAbstract: The death rate of patients with ST-segment elevation myocardial infarction (STEMI) remains substantial.
Alexander GG Turpie
doaj +1 more source
Management of acute coronary syndromes with fondaparinux
Vascular Health and Risk Management, 2007 Harm Wienbergen, Uwe ZeymerHerzzentrum Ludwigshafen, Medizinische Klinik B, GermanyAbstract: Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use.
Harm Wienbergen, Uwe Zeymer
doaj +1 more source
FONDAPARINUX USAGE IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME [PDF]
Российский кардиологический журнал, 2015 Anticoagulation treatment is a vital component of acute coronary syndrome treatment. Selection of the most efficient and safe drug for the acute coronary syndrome patients without ST elevation (NSTEACS) depends on the strategy of treatment and is in fact
G. V. Mardaryan, S. A. Abugov
doaj +2 more sources
Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients
Drug Design, Development and Therapy, 2016 Bruno Amato,1,2,* Rita Compagna,1,2,* Aldo Rocca,2 Tommaso Bianco,2 Marco Milone,2 Luigi Sivero,2 Gabriele Vigliotti,2 Maurizio Amato,2 Michele Danzi,2 Giovanni Aprea,2 Luca Gallelli,3,* Stefano de Franciscis,1,4,* Raffaele Serra1,4,* 1Interuniversity ...
Amato B +12 more
doaj +2 more sources
Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. [PDF]
, 2017 BACKGROUND Life-threatening heparin-induced thrombocytopenia (HIT) is treated with the alternative nonheparin anticoagulants argatroban, lepirudin, or danaparoid. Frequently, the pentasaccharide fondaparinux is used off-label.
Schindewolf, Marc +44 more
core +2 more sources
Jurnal Farmasi dan Ilmu Kefarmasian Indonesia, 2019 Pendahuluan: Fondaparinux 2,5 mg sebagai terapi antikoagulan pada pasien Sindroma Koroner Akut (SKA) di RSUD Dr. Soetomo Surabaya diberikan selama 5 hari, sedangkan pustaka menyebutkan bahwa fondaparinux diberikan selama 3 - 7 hari.
Arina Dery Puspitasari +2 more
doaj +1 more source
Frontiers in Endocrinology, 2021 BackgroundTo compare the clinical efficacy of fondaparinux and LMWH and provide clinical evidence for the effectiveness of fondaparinux in the treatment of recurrent spontaneous abortion caused by PTS.MethodsA retrospective analysis was conducted for 120
Long Zhao +5 more
doaj +1 more source